Ivonescimab vs JS207
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 + VEGFA · full Non-Small Cell Lung Cancer pipeline
Ivonescimab
Marketed by Akeso and partners
NCT05499390 · Phase 3 · active, not recruiting
This trial randomized patients in a quadruple-blinded design comparing ivonescimab against an active comparator (pembrolizumab), with nearly 400 participants -- a reasonably powered sample for a Phase 3 oncology trial. The primary endpoint, progression-free survival by independent blinded review, is a hard clinical measure, and the result was statistically significant in favor of ivonescimab (11.1 vs 5.8 months, hazard ratio 0.51, p<0.0001), indicating a clear and well-supported benefit.
Next expected readout: December 2026 · NCT07086326 (registry estimate)
Reported efficacy
PFS assessed by IRRC per RECIST v1.1 (Up to 2 approximately years): HARMONi-2 (NCT05499390), independent-review PFS at the interim analysis: ivonescimab 11.1 vs pembrolizumab 5.8 months; HR 0.51 (95% CI 0.38-0.69), one-sided p<0.0001; 398 randomized (met)
Result source: NCT05499390
JS207
Developed by Shanghai Junshi Bioscience
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT06944470 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ivonescimab | JS207 |
|---|---|---|
| PFS, median | —Trial running · NCT05840016 | —Not reported |
| OS, median | —Trial running · NCT05840016 | —Not reported |
| ORR | —Trial running · NCT05840016 | —Not reported |
| Duration of response, median | —Trial running · NCT05840016 | —Not reported |
PFS, median
- Ivonescimab
- —Trial running · NCT05840016
- JS207
- —Not reported
OS, median
- Ivonescimab
- —Trial running · NCT05840016
- JS207
- —Not reported
ORR
- Ivonescimab
- —Trial running · NCT05840016
- JS207
- —Not reported
Duration of response, median
- Ivonescimab
- —Trial running · NCT05840016
- JS207
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
JS207: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ivonescimab's landscape · JS207's landscape